share_log
Reuters ·  May 25 09:41
Vera Therapeutics Presents 72-Week Egfr Stabilization and Rapid Hematuria Improvement in Phase 2B Origin Study of Atacicept in Igan at the 61St European Renal Association Congress
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment